AKBA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AKBA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive elements, including strong revenue growth in the latest quarter and positive analyst ratings, but the current technical trend is still weak and the options market is more consistent with speculation than durable long-term conviction. With no major news catalyst, no insider or congress buying signal, and no Intellectia proprietary buy signal today, the better call is to hold and wait for clearer confirmation rather than buy immediately.
The short-term trend is bearish. MACD histogram is below zero and expanding negatively, RSI_6 at 40.21 is neutral but not strong enough to signal momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 1.39 is below the pivot at 1.415 and only slightly above support at 1.345, which means the stock is sitting close to support but has not yet reversed trend convincingly. The near-term pattern estimate is also mixed to weak, with roughly flat performance expected over the next month. Overall, the chart does not support an immediate long-term entry.
["Latest quarter revenue increased 23.93% YoY in 2025/Q4.", "Gross margin improved sharply to 82.06%.", "Analysts still maintain positive ratings: BTIG Buy and Piper Sandler Overweight.", "Options positioning is bullish, with put-call ratios heavily skewed toward calls.", "Stock remains near support, which could offer downside-limited entry if momentum improves."]
["Net income worsened to -12.24M and EPS declined to -0.05 in 2025/Q4.", "MACD is negative and weakening, showing poor momentum.", "Moving averages are bearish, indicating the broader trend is still down.", "BTIG and Piper Sandler both cut price targets to $4 from higher levels, showing softer expectations.", "No news in the recent week, so there is no fresh catalyst to drive a sustained move.", "No recent insider, hedge fund, or congress buying/selling signal that would strengthen conviction."]
In 2025/Q4, Akebia showed solid top-line growth with revenue rising to 57.62M, up 23.93% YoY, and gross margin expanding to 82.06%. However, profitability remains weak because net income fell to -12.24M and EPS declined to -0.05. This shows improving commercial growth but continued losses, which is acceptable for a speculative growth story but not strong enough yet for a confident beginner long-term purchase.
Recent analyst trend is still positive but less aggressive than before. BTIG lowered its target to $4 from $5 while keeping a Buy rating, and Piper Sandler lowered its target to $4 from $6 while maintaining Overweight. That suggests Wall Street still sees upside, but expectations have been trimmed. The pros view is that revenue growth and commercial progress remain intact; the cons view is that revenue recognition and channel inventory issues are limiting near-term upside.
